These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Gastroenteropancreatic Neuroendocrine Tumors. Cives M; Strosberg JR CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930 [TBL] [Abstract][Full Text] [Related]
28. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. Pencharz D; Gnanasegaran G; Navalkissoor S Br J Radiol; 2018 Nov; 91(1091):20180108. PubMed ID: 30102557 [TBL] [Abstract][Full Text] [Related]
29. The Search for an Alternative to [ Waldmann CM; Stuparu AD; van Dam RM; Slavik R Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834 [TBL] [Abstract][Full Text] [Related]
31. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J Eur J Cancer; 2021 Mar; 146():56-73. PubMed ID: 33588146 [TBL] [Abstract][Full Text] [Related]
32. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. Deroose CM; Hindié E; Kebebew E; Goichot B; Pacak K; Taïeb D; Imperiale A J Nucl Med; 2016 Dec; 57(12):1949-1956. PubMed ID: 27811124 [TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine Tumors: Diagnostics. Sakellis C; Jacene HA PET Clin; 2024 Jul; 19(3):325-339. PubMed ID: 38714399 [TBL] [Abstract][Full Text] [Related]
34. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging. Baumann T; Rottenburger C; Nicolas G; Wild D Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843 [TBL] [Abstract][Full Text] [Related]
35. Overview and Current Status of Peptide Receptor Radionuclide Therapy. Bushnell DL; Bodeker KL Surg Oncol Clin N Am; 2020 Apr; 29(2):317-326. PubMed ID: 32151363 [TBL] [Abstract][Full Text] [Related]
36. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT. Kulkarni HR; Baum RP PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937 [TBL] [Abstract][Full Text] [Related]
37. Peptide receptor therapies in neuroendocrine tumors. Bodei L; Ferone D; Grana CM; Cremonesi M; Signore A; Dierckx RA; Paganelli G J Endocrinol Invest; 2009 Apr; 32(4):360-9. PubMed ID: 19636207 [TBL] [Abstract][Full Text] [Related]
38. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Sundin A Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):803-18. PubMed ID: 23582920 [TBL] [Abstract][Full Text] [Related]
39. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Alexandraki KI; Karapanagioti A; Karoumpalis I; Boutzios G; Kaltsas GA Biomed Res Int; 2017; 2017():9856140. PubMed ID: 29349087 [TBL] [Abstract][Full Text] [Related]
40. Molecular and Anatomic Imaging of Neuroendocrine Tumors. Szidonya L; Park EA; Kwak JJ; Mallak N Surg Oncol Clin N Am; 2022 Oct; 31(4):649-671. PubMed ID: 36243499 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]